For Elfin, the sale of branded formulations in India is an integral part of business operations, which contributed little over 35% to the company’s sales income for FY 2013. India is one of the fastest growing pharmaceutical markets in the world, it is a major growth driver for the company.
Company’s clear focus on specialty segments of Ophthalmology, Dermatology
, and Cardiovascular has enabled it to continue to grow at much higher rates over industry average growth rate of the Indian Pharmaceutical Market (IPM) for last 5 years. Our competency in identifying unmet medical needs and then being first-to-market many products has been our foundation for success throughout these years and will continue to be so in the coming years.